Regeneron Pharmaceuticals Inc. Common Stock (REGN)
Stock · NASDAQ · Health Care
$791.25as of 10/16/2026
Price chart
Active signals
Support level
$742.26
Industry
Biotechnology: Pharmaceutical Preparations
REGN Signal Track Record
How signals performed across all stocks →What REGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +0.9% | 53% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +1.6% | 56% | September 2, 2026 |
| Bollinger Band Breakdown | 18 | -2.0% | 33% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -0.5% | 50% | October 1, 2026 |
| Any 20-session window (baseline) | +0.9% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic mac…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 15,410
- Website
- www.regeneron.com/
Fundamentals
- 1-day range
- $787.33$805.68
- Market cap
- $79.49B
- P/E (trailing)
- 19.00
- P/E (forward)
- 12.77
- EPS (trailing)
- $40.45
- Dividend yield
- 0.46%
- Beta
- 0.14
- Avg. volume
- 743.8K
- Ex-dividend date
- August 18, 2026
- Dividend pay date
- August 31, 2026
52-week range
$564$859.34
Next earnings: October 30, 2026 · EPS estimate $16.06confirmed
How Regeneron Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 4, 2026 · via SEC EDGAR / Finnhub
Gross Profit$12.24B(85%)
Operating Income$3.58B(25%)
Forecasts
27 analyst ratings
Buy 68%
Hold 32%
Sell 0%
1-year price forecast
High
$1,030
+30.2%
Median
$860
+8.7%
Low
$730
-7.7%
Regeneron Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- REGNRegeneron Pharmaceuticals Inc. Common Stock$790.74▼ 0.70%Market cap $79.49BP/E 19.00$564$859.34
- SNYSanofi ADS$40.61▲ 0.79%Market cap $104.60BP/E 21.77$69.75$91.15
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$19.67▲ 1.13%Market cap $53.78BP/E —$4,102$6,183
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
- TEVATeva Pharmaceutical Industries Limited American Depositary Shares$41.5▲ 0.95%Market cap $40.56BP/E 68.57$6,207$12,990
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 19.00 | $790.74 | ▼ 0.70% | $564$859.34 |
| SNY Sanofi ADS | $104.60B | 21.77 | $40.61 | ▲ 0.79% | $69.75$91.15 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $19.67 | ▲ 1.13% | $4,102$6,183 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $40.56B | 68.57 | $41.5 | ▲ 0.95% | $6,207$12,990 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Is Vertex Stock Worth More Than Its Competitors?Yahoo · 10/9/2026
- What Is Going On With Regeneron Stock?Yahoo · 10/9/2026
- Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKDYahoo · 10/8/2026
- RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810Benzinga · 10/8/2026
- Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?Yahoo · 10/8/2026
- Regeneron CEO on R&D, Data and OmicsYahoo · 10/7/2026
- Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780Benzinga · 10/7/2026
- Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779Benzinga · 10/7/2026
- This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursdaybenzinga · 10/1/2026
Insider Activity
Insider Actions →Acquired
20.2K
Disposed
17.8K
- Marion McCourt · September 3, 2026 · Sale1.1K @ $857.39
- Kathryn Guarini · September 2, 2026 · Sale400 @ $850
- Marion McCourt · September 2, 2026 · Sale1.2K @ $850
- Kathryn Guarini · September 2, 2026 · Option Exercise400 @ $719.37
- Joseph J. Larosa · August 19, 2026 · Option Exercise12.3K @ $381.92
- Joseph J. Larosa · August 19, 2026 · Tax Withholding9.0K @ $830.15
- Christopher R. Fenimore · August 18, 2026 · Option Exercise6.3K @ $381.92
- Christopher R. Fenimore · August 18, 2026 · Tax Withholding4.6K @ $813.47
- Kathryn Guarini · August 10, 2026 · Option Exercise400 @ $719.37
- Kathryn Guarini · August 10, 2026 · Sale400 @ $800
- Huda Y. Zoghbi · August 10, 2026 · Option Exercise800 @ $376.69
- Huda Y. Zoghbi · August 10, 2026 · Sale800 @ $800
- Arthur F. Ryan · July 2, 2026 · Sale200 @ $650.15
- Arthur F. Ryan · May 1, 2026 · Sale1 @ $712.09
- Arthur F. Ryan · May 1, 2026 · Sale5 @ $701.76
Institutional Ownership
March 31, 2026
- Total shares held
- 83.07M
- Total value held
- $61.14B
- Institutional holders
- 1377
Top holders this quarter
- Unknown8.95M
- Unknown6.65M
- Unknown4.66M
- Unknown4.46M
- Unknown2.72M
- Unknown2.61M
- Unknown2.18M
- Unknown2.07M
- Unknown1.91M
- Unknown1.84M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.